Galectin Therapeutics Inc.
Hedge Funds Holdings
Last updated:
Galectin Therapeutics Inc.‘s stocks are currently a part of 54 hedge funds’ portfolios, which represents 12.75% of the total amount of its stocks outstanding. This makes up a total of 7.46M shares of Galectin Therapeutics Inc.. Compared to the previous quarter, the number grew by 1.87% or 137.21K shares more. As for the holding position changes, 24.07% (13) of current hedge fund investors increased the number of shares held, 31.48% (17) of current holders sold a part of the shares held, and 9.26% (5) closed the holdings completely. 9 hedge funds are new holders of Galectin Therapeutics Inc. stock in Q1 2022, it is 16.67% of total holders.
Hedge funds holding Galectin Therapeutics (Q2 2017 – Q1 2022)
| Q2 2017 | 48 |
|---|---|
| Q3 2017 | 45 |
| Q4 2017 | 46 |
| Q1 2018 | 57 |
| Q2 2018 | 66 |
| Q3 2018 | 58 |
| Q4 2018 | 58 |
| Q1 2019 | 62 |
| Q2 2019 | 71 |
| Q3 2019 | 74 |
| Q4 2019 | 73 |
| Q1 2020 | 70 |
| Q2 2020 | 73 |
| Q3 2020 | 68 |
| Q4 2020 | 74 |
| Q1 2021 | 72 |
| Q2 2021 | 71 |
| Q3 2021 | 66 |
| Q4 2021 | 51 |
| Q1 2022 | 54 |
Hedge funds changes in Galectin Therapeutics positions (Q2 2017 – Q1 2022)
| Q2 2017 | 10 | 10 | 7 | 3 | 18 |
|---|---|---|---|---|---|
| Q3 2017 | 5 | 8 | 8 | 7 | 17 |
| Q4 2017 | 8 | 6 | 16 | 7 | 9 |
| Q1 2018 | 20 | 10 | 9 | 9 | 9 |
| Q2 2018 | 19 | 19 | 15 | 10 | 3 |
| Q3 2018 | 13 | 20 | 11 | 21 | -7 |
| Q4 2018 | 12 | 15 | 11 | 12 | 8 |
| Q1 2019 | 17 | 15 | 14 | 12 | 4 |
| Q2 2019 | 25 | 23 | 14 | 15 | -6 |
| Q3 2019 | 11 | 29 | 19 | 9 | 6 |
| Q4 2019 | 8 | 25 | 10 | 9 | 21 |
| Q1 2020 | 8 | 16 | 20 | 8 | 18 |
| Q2 2020 | 10 | 23 | 17 | 7 | 16 |
| Q3 2020 | 4 | 13 | 26 | 9 | 16 |
| Q4 2020 | 10 | 22 | 18 | 4 | 20 |
| Q1 2021 | 8 | 14 | 25 | 10 | 15 |
| Q2 2021 | 21 | 13 | 18 | 22 | -3 |
| Q3 2021 | 9 | 11 | 22 | 14 | 10 |
| Q4 2021 | 7 | 15 | 11 | 20 | -2 |
| Q1 2022 | 9 | 13 | 17 | 5 | 10 |
Hedge funds changes in Galectin Therapeutics stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 866,000 | 248,000 |
|---|---|---|
| Q3 2017 | 523,000 | 289,000 |
| Q4 2017 | 1,336,000 | 179,000 |
| Q1 2018 | 1,119,000 | 663,000 |
| Q2 2018 | 1,173,000 | 2,776,000 |
| Q3 2018 | 2,911,000 | 2,834,000 |
| Q4 2018 | 1,301,000 | 1,839,000 |
| Q1 2019 | 2,038,000 | 2,230,000 |
| Q2 2019 | 894,000 | 1,249,000 |
| Q3 2019 | 665,000 | 994,000 |
| Q4 2019 | 453,000 | 736,000 |
| Q1 2020 | 321,000 | 154,000 |
| Q2 2020 | 442,000 | 187,000 |
| Q3 2020 | 648,000 | 183,000 |
| Q4 2020 | 436,000 | 293,000 |
| Q1 2021 | 226,000 | 220,000 |
| Q2 2021 | 1,800,000 | 609,000 |
| Q3 2021 | 2,841,000 | 1,016,000 |
| Q4 2021 | 759,000 | 299,000 |
| Q1 2022 | 450,000 | 204,000 |